Immix Biopharma announced that it has shipped Good Manufacturing Practice, GMP, manufactured batches of Tislelizumab for clinical trial patient dosing. Tislelizumab, Beigene/Novartis anti-PD-1 antibody, will be combined with IMX-110 in a clinical trial for patients with advanced solid tumors. GMP manufactured IMX-110 was already released and shipped on December 12, 2022. "Having shipped both IMX-110 and Tislelizumab to sites completes drug supply preparations and puts us on a launching pad for this exciting combination clinical trial," said Ilya Rachman, MD PhD, CEO of ImmixBio. "We expect to begin reporting clinical data from this trial beginning in Q1 2023."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMMX:
- Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
- ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
- Immix Pops After “In-Licensing” Cancer Cell Therapy
- Immix Biopharma announces is has in-licensed NXC-201
- Immix Biopharma announces patient dosing in Phase 1b/2a IMX-110 trial